RxDoctor Payments Data

Douglas Klingler, MD

Urology · Lawrence, KSNPI 1811926595

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,364 of the $3,710 with a category attached, or 63.7%. 20 manufacturers reported payments, led by Olympus Corporation Of The Americas at 28.9% of the total.

$3,710in general payments, 2019–2025

Across 62 payments — averaging $59.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$1K
  • Procept Biorobotics Corporation$711
  • Cook Incorporated$677
  • Cook Medical LLC$381
  • Axonics, Inc.$251
  • Sumitomo Pharma America, Inc.$84
  • plus $537 from 14 others

What the payments were for

  • Travel & lodging$2,36464%
  • Food & beverage$1,34736%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,710 in reported general payments places this provider in the 60th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$312,343
Medicare patients
739
Services billed
5,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron220$117,308
GemtesaVibegron109$65,273
ElmironPentosan Polysulfate Sodium13$16,527
Tamsulosin Hcl618$8,685
Alfuzosin Hcl ErAlfuzosin Hcl181$4,072
Trospium Chloride ErTrospium Chloride20$3,470
Silodosin35$3,456
Trospium Chloride89$3,164
Fesoterodine Fumarate ErFesoterodine Fumarate42$2,511
Methenamine Hippurate35$2,268
Finasteride181$2,229
Oxybutynin Chloride ErOxybutynin Chloride115$2,228
Testosterone Cypionate26$961
Solifenacin Succinate33$531
Cefdinir71$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$33$117,308220 claims
Sumitomo Pharma America, Inc.Gemtesa$84$65,273109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 111 urology providers in Kansas.

Other urology in Lawrence

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →